NEWARK, DE |—The long-acting implantable GLP-1 obesity devices market is valued at USD 59.1 million in 2025 and is projected to reach USD 76.0 million in 2026. Expanding at a robust CAGR of 28.50%, the market is expected to surge to USD 932.9 million by 2036. This growth reflects a fundamental shift in obesity care delivery, as stakeholders prioritize long-term therapy persistence over short-term efficacy.

The long-acting implantable GLP-1 obesity devices market is gaining traction as healthcare systems address real-world patient adherence challenges. By transitioning from patient-administered injectables to physician-controlled, continuous-release implants, the market is redefining obesity treatment economics and clinical workflows.

Market snapshot: global market 2026 - 2036

• Market size 2026: USD 76.0 Million
• Market size 2036: USD 932.9 Million
• CAGR (2026–2036): 28.50%
• Leading product segments: baking accessories 25.6% and grilling & frying 45.1%
• Leading material type: 58.1% disposable
• Leading end use: 51.9% residential
• Key growth regions: North America, Europe, Asia Pacific
• Top companies: Vivani Medical, Inc., DelSiTech Ltd., Delpor, Inc., Evonik Health Care, Corbion, Ashland Inc., Poly-Med, Inc.

Market Momentum (YoY Path)

The long-acting implantable GLP-1 obesity devices market demonstrates a steep upward trajectory beginning at USD 59.1 million in 2025 and reaching USD 76.0 million in 2026. By 2028, the market begins scaling as early clinical validation strengthens, followed by accelerated adoption in 2030 and 2031 as regulatory pathways mature. Growth intensifies through 2033 with expanded clinical deployment, ultimately reaching USD 932.9 million by 2035, signaling the transition from precommercial validation to large-scale commercialization.

Why the Market is Growing

Growth in the long-acting implantable GLP-1 obesity devices market is driven by the urgent need to address therapy abandonment in obesity care. Managed care organizations are shifting toward delivery systems that eliminate patient-controlled dosing. Additionally, the high cost of unused injectable therapies is pushing procurement teams toward single-intervention solutions. Continuous-release polymer platforms also offer developers a scalable pathway to monetize proprietary drug delivery technologies.

Segment Spotlight

Product Type
Grilling & frying accounts for 45.1% share, reflecting dominant demand dynamics. In parallel, exenatide implants lead with 54.0% share due to their established safety profile, making them ideal for validating implant-based delivery systems. Developers rely on these legacy molecules to isolate mechanical safety and streamline regulatory approval.

Material Type
Disposable materials hold a 58.1% share, aligning with the need for hygiene and simplified clinical workflows. In the implant context, subdermal NanoPortal-type solid implants dominate with 41.0% share due to predictable release kinetics and retrievability, ensuring safety and compliance.

End Use
Residential usage leads with 51.9% share, reflecting broader adoption trends. Within clinical settings, specialty obesity and endocrinology clinics account for 47.0% share, supported by their capability to perform minor surgical procedures and manage long-term metabolic therapies effectively.

Drivers, Opportunities, Trends, Challenges

Drivers
The primary growth driver is the high rate of real-world therapy discontinuation. Payers are demanding solutions that ensure 12-month persistence, pushing the adoption of implantable delivery systems over traditional injectables.

Opportunities
Significant opportunities exist in biomaterial integration and next-generation peptide formulation. CDMO partners capable of producing ultra-pure polymers are positioned to secure high-value contracts, while dual-action implant formulations open new therapeutic possibilities.

Trends
A key trend is the transition from pharmacy-based distribution to physician-administered procedural models. This shift is reshaping reimbursement structures and aligning treatment delivery with clinical oversight.

Challenges
The main challenge is the operational shift to minor surgical procedures. Limited procedural training, lack of dedicated time slots, and evolving reimbursement codes are slowing broader adoption outside specialized clinics.

Country Growth Outlook (CAGR)

Competitive Landscape

The long-acting implantable GLP-1 obesity devices market is highly concentrated due to significant technical and capital barriers. Early leaders such as Vivani Medical, Inc., DelSiTech Ltd., and Delpor, Inc. dominate through validated clinical data and proprietary delivery platforms. Material science leaders including Evonik Health Care, Corbion, and Ashland Inc. play a critical role in supplying specialized polymers. The market is expected to consolidate further as large biopharmaceutical companies pursue vertical integration to secure long-term competitive advantage.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates:https://www.futuremarketinsights.com/reports/brochure/rep-gb-32361

Get Access of Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-32361

Scope of the Report

• Market size: USD 76.0 Million (2026) to USD 932.9 Million (2036)
• CAGR: 28.50% (2026–2036)
• Segmentation: Molecule Type, Duration Profile, Technology Platform, Care Setting, End-user Group
• Regions: North America, Europe, Asia Pacific
• Countries: China, India, Australia, United States, United Kingdom, Germany, Japan, and 40+ others
• Key companies: Vivani Medical, Inc., DelSiTech Ltd., Delpor, Inc., Evonik Health Care, Corbion, Ashland Inc., Poly-Med, Inc.

FAQ

How large is the market in 2026?
The long-acting implantable GLP-1 obesity devices market is valued at USD 76.0 million in 2026, reflecting its early-stage, clinical-validation phase.

What will the market be worth by 2036?
It is projected to reach USD 932.9 million by 2036, driven by regulatory approvals and large-scale adoption.

What is the expected CAGR?
The market is expected to grow at a CAGR of 28.50% between 2026 and 2036.

Which molecule type leads the market?
Exenatide implants lead with a 54.0% share due to their established safety and suitability for early-stage validation.

Which duration profile dominates?
6-month implants lead with a 58.0% share, aligning with clinical workflows and billing cycles.

What drives market growth?
Growth is driven by the need to solve therapy discontinuation and ensure long-term treatment adherence.

What is the key challenge?
The transition from prescription-based models to procedural interventions remains the primary operational hurdle.

Which country grows the fastest?
China leads with a CAGR of 32.4%, followed by India at 31.6%.

Explore More Related Studies Published by FMI Research:

Hydrocephalus Shunt Market: https://www.futuremarketinsights.com/reports/hydrocephalus-shunt-market

Endoscopic Closure Systems Market: https://www.futuremarketinsights.com/reports/endoscopic-closure-systems-market

Mammalian Transient Protein Expression Market: https://www.futuremarketinsights.com/reports/mammalian-transient-protein-expression-market

Home Sleep Apnea Testing Market: https://www.futuremarketinsights.com/reports/home-sleep-apnea-testing-market

Lacrimal Devices Market: https://www.futuremarketinsights.com/reports/lacrimal-devices-market

About Future Market Insights (FMI)

 Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Contact Us:    

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com